#1
|
|||
|
|||
Àíàëèç íà ðåçóñ ôàêòîð ïëîäà
Ó ìåíÿ - ó ìóæà +,âòîðàÿ áåðåìåííîñòü,óçíàëà ÷òî ñåé÷àñ ìîæíî ñäåëàòü òàêîé àíàëèç.(Áåðóò êðîâü èç âåíû ó ìàìû)
Íà ñêîëüêî îí äîñòîâåðåí? |
#2
|
||||
|
||||
Âû íå ñîâñåì ïðàâèëüíî ïîíÿëè.  Âàøåé êðîâè áóäåò îïðåäåëÿòüñÿ òèòð àíòèðåçóñíûõ àíòèòåë, à íå ðåçóñ-ôàêòîð ïëîäà. Ïî÷èòàéòå ïîèñêîì ïî ôîðóìó ïðî ðåçóñ-êîíôëèêò.
Òåìó ïåðåíîøó â ïðîôèëüíûé ðàçäåë. |
#3
|
|||
|
|||
Íåò ÿ âñ¸ ïðàâèëüíî ïîíåëà,ÿ íå ïóòàþ àíàëèç,íà àíòèòåëà ÿ è â ïðîøëóþ Á ñäàâàëà.À ýòîò àíàëèç òàê è íàçûâåòñÿ
âîò êîïèðóþ ñ ñàéòà ìåäëàáîðîòîðèè ãäå äåëàþò Ðåçóñ-ôàêòîð (RhD) (ÃÅ49) Îïðåäåëåíèå ðåçóñ- ôàêòîðà ïëîäà 300,00 ðóá. (ÃÅ50) Ãåíîòèïèðîâàíèå ñèñòåìû RhD 300,00 ðóá. Ýòî íå òàê äîâíî ñòàëè äåëàòü è íå âñå âèäèìî åùå çíàþò. ññûëêó íà ëàáàðàòîðèþ òîæå ìîãó äàòü,åñëè ìîäåðàòîðû ðàçðåøàò. |
#4
|
|||
|
|||
Äîñòîâåðíîñòü àíàëèçà çàâèñèò îò ìåòîäà îïðåäåëåíèÿ. Äàéòå ññûëêó.
|
#5
|
|||
|
|||
âîò îäíà èç ðàáîò
Transfus Med Rev. 2003 Jan;17(1):31-44. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed. van der Schoot CE, Tax GH, Rijnders RJ, de Haas M, Christiaens GC. Department of Experimental Immunohematology, Sanquin Division, CLB and Laboratory for Experimental and Clinical Immunology, Academic Medical Center, University of Amsterdam, The Netherlands. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Knowledge of the molecular basis of the blood group systems has enabled the development of assays for blood group genotyping. At this time, polymerase chain reaction (PCR)-based assays validated on fetal material obtained by invasive means (chorionic villus sampling or amniocentesis) are available for all clinically relevant fetal blood groups, However, only Rh typing (D, C, c, E, and e) and K1 genotyping assays are discussed in this review. Importantly, one must remember that results of genotyping assays will not always be concordant with serological typing. Thus, the RhD genotyping assays have to be modified in response to increased understanding of the molecular biology of this blood group system. RhD typing assays should produce negative results when tested on the black RhD-negative RHD alleles, RHDpsi and r's. PCR-based assays can be used to determine paternal zygosity. For RhD zygosity testing, the real-time quantitative PCR approach and the direct detection of the hybrid Rhesus box, which is the result of the deletion of the RHD gene are available. Recently, methods for noninvasive prenatal genotyping have been investigated. The use of fetal cells circulating in the maternal circulation has been explored; however, the scarcity of circulating fetal cells has limited the use of this approach. More promising are the results obtained with RhD typing assays with cell-free fetal DNA, which is present in the maternal circulation in a concentration of 25 genomic equivalents per milliliter of maternal blood in early pregnancy increasing to 100 copies per milliliter in the third trimester, which is cleared from the circulation within a few hours of delivery. The positive predictive value of this approach is virtually 100%, but false-negative results are (infrequently) encountered. Therefore, this assay can at present only be used for screening of RhD-negative women to make the use of antenatal prophylaxis more targeted and hence more cost-effective. For the clinical management of the pregnancies of alloimmunized women, the development of a control for the presence and the amplification of fetal DNA is needed, which is at present only available in male pregnancies. Assays for the genotyping of the other Rh antigens or Kell antigens with cell-free fetal DNA have not yet been described. Copyright 2003, Elsevier Science (USA). All rights reserved. |
#6
|
|||
|
|||
Âîò òóò åãî äåëàþò
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (¹¹¹ óáðàòü) ß åãî ñåãîäíÿ óæå ñäåëàëà,ðåçóëüòàò áóäåò ÷åðåç 3 íåäåëè ãîòîâ. |
#7
|
|||
|
|||
Óâàæàåìàÿ yasy,
åñòü ñîìíåíèÿ â òîì, êàêèì èìåííî ìåòîäîì âûïîëíÿåòñÿ àíàëèç, äîïîëíèòåëüíîé èíôîðìàöèè íà ñàéòå íåò, âîçìîæíû ëîæíî-îòðèöàòåëüíûå ðåçóëüòàòû. Ïîýòîìó ëó÷øå íå ïðèíèìàòü êëèíè÷åñêèõ ðåøåíèé ïðè îòðèöàòåëüíîì ðåçóëüòàòå (ò.å. îòêàç îò èììóíèçàöèè àíòè-D). |
|
#8
|
|||
|
|||
Ñïàñèáî çà îòâåò.
À åñëè ïåðâûé ðåáåíîê (-),òî ìîæíî íå äåëàòü àíòè-D? Ó ìåíÿ âîîáùå ýòî áåðåìåííîñòü âòîðàÿ,ò.å. íè àáîðòîâ,íè âûêèäûøåé íå áûëî. Ó íàñ åãî î÷åíü òðóäíî íàéòè â (Ïèòåðå) äà è öåíà íà íåãî îêîëî 13000 ò.ðóá,íå õîòåëîñü áû êîëîòü çà çðÿ. |
#9
|
|||
|
|||
Âîò ïîëó÷èëà ÿ àíàëèç
Ðåçóëüòàòû ãåíåòè÷åñêîãî òåñòèðîâàíèÿ: Ñïðàâî÷íàÿ Ãåí Ïîëèìîðôèçì Ãåíîòèï ýôôåêò èíôîðìàöèÿ Ðåçóñ-ôàêòîð (RhD) RhD (ÃÅ49) Îïðåäåëåíèå ðåçóñ- ôàêòîðà ïëîäà +RhD ïîëîæèòåëüíûé ðåçóñ-ôàêòîð ïëîäà RhD (ÃÅ50) Ãåíîòèïèðîâàíèå ñèñòåìû RhD d/d RhD- (îòðèöàòåëüíûé) Çàêëþ÷åíèå: Îòðèöàòåëüíûé ðåçóñ-ôàêòîð áåðåìåííîé.  ïëàçìå êðîâè áåðåìåííîé âûÿâëåíû ñïåöèôè÷åñêèå RhD+ ôðàãìåíòû ÄÍÊ ïëîäà. Ïðåäïîëîæèòåëüíî, ïëîä ðåçóñ ïîëîæèòåëüíûé. Ðèñê ÃÁÍ ñîñòàâëÿåò 25%. Ðåêîìåíäóåòñÿ ïðîâåäåíèå èììóííîëîãè÷åñêîãî è ÓÇÈ êîíòðîëÿ çà ñîñòîÿíèåì ïëîäà. Ïîêàçàíî ïðîâåäåíèå àíòè-ðåçóñ èììóíèçàöèè. Ïðèìå÷àíèå: 24 íîÿáðÿ 2009 |
#10
|
|||
|
|||
Ïîêàçàíî èññëåäîâàíèå àíòèðåçóñíûõ àíòèòåë, äàëüíåéøèå ðåøåíèÿ ïðèíèìàþòñÿ â çàâèñèìîñòè íàëè÷èÿ/îòñóòñòâèÿ è òèòðà ýòèõ àíòèòåë.
Ñîãëàñèòüñÿ ñ îöåíêîé ðèñêà ÃÁÍ â 25% íåâîçìîæíî. |
#11
|
|||
|
|||
|
#12
|
|||
|
|||
Ðèñê ÃÁÍ íàìíîãî íèæå 25%, âåðîÿòíî îò 2 äî 7%, åñëè íå áóäåò ââîäèòñÿ àíòè-Ä è îêîëî 0,1% ïðè ââåäåíèè àíòè-Ä íà 28 íåäåëå (ýòî, êîíå÷íî, ïðè óñëîâèè îòñóòñòâèÿ àíòèðåçóñíûõ àíòèòåë).
|
#13
|
|||
|
|||
Ôóõ,ñïàñèáî,à òî ýòè 25% ìåíÿ ïðÿìî íàïðÿãëè.Áóäó äåëàòü àíòè-Ä,åñëè àíòèòåë äàé Áîã íå áóäåò.
|
#14
|
|||
|
|||
Âîïðîñ ïî ïîâîäó àíòèðåçóñíîãî èìóíóãëîáóëèíà
Ìîæíî ëè óêîëîòü â 30 íåäåëü âîò ýòîò [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] åñòü âîçìîæíîñòü ïðèâåçòè èç Ãåðìàíèè
Âìåñòî Ãèïåð Ðîó, â Ïèòåðå îí òîëüêî çà áåøåííûå äåíüãè,îêîëî 17000 ðóáëåé ñòîèò. |
#15
|
|||
|
|||
Íèêòî íå ìîæåò ïîìî÷ü...èëè ýòî ìû íå ïðîõîäèëè,ýòî íàì íå çàäàâàëè.
|